Abaxis To Report Fourth Quarter And Fiscal Year 2014 Financial Results Thursday, April 24, 2014
PR Newswire - Tue Apr 15, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, has scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2014, ended March 31, 2014. The call will be at 4:15 p.m. ET on Thursday, April 24, 2014. The Company will report financial results for the fourth quarter and fiscal year 2014 after the market closes on Thursday, April 24, 2014.
Abaxis' Piccolo Xpress Gets Health Canada Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 2:30PM CDT
Abaxis' Piccolo Xpress gets Class III approval from Health Canada.
Abaxis receives Health Canada Class III approval for Piccolo Xpress
M2 - Wed Apr 09, 5:35AM CDT
US-based medical products company Abaxis (NasdaqGS:ABAX) reported on Tuesday the receipt of Health Canada's approval for the Piccolo Xpress and Piccolo Reagent Discs as a Class III medical devices for use throughout Canada.
Abaxis Receives Health Canada Class III Approval for Piccolo Xpress®
PR Newswire - Tue Apr 08, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today announced Health Canada approved the Piccolo Xpress® and Piccolo Reagent Discs as a Class III medical device for use throughout Canada. With this reclassification, Canadian healthcare providers and patients can now enjoy the benefits of lab-accurate blood chemistry diagnostics at the point-of-care.
Point-Of-Care Diagnostic Market Forecasts & Opportunities, 2018
M2 - Fri Apr 04, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cd9kt8/pointofcare) has announced the addition of the "Point-Of-Care Diagnostic Market Forecasts & Opportunities, 2018" report to their offering. The global point-of-care diagnostics market is dominated by North America, followed by Europe, Asia-Pacific and the Rest of the World (RoW). North America will continue to dominate the market in the forecast period, followed by the Asia-Pacific. However, the Asia-Pacific region is expected to grow at the highest CAGR of -13.6% from 2013 to 2018. Over the next five years, the growth of the market in the Asia-Pacific region is likely to be centered at Japan, China, and India. A number of factors such as the huge patient population base, increasing funding/investment toward the development of point of care diagnosticproducts, growing focus of both international and domestic players on the Asia-Pacific point-of-care diagnostics market, and large number of R&D activities are driving the growth of the market in the Asia-Pacific region. A number of factors such as the rising prevalence of lifestyle and infectious diseases, increasing usage of home-based POC devices, and decreasing number of technicians in central labs are driving the growth of the global market. Furthermore, growing government support and increasing private investments and venture funding to support new product development are other factors that are propelling the growth of the market. In addition, rising adoption of POC devices, expansion of therapeutic horizon, and technological advancements is further fueling the growth of this market. However, a few pivotal factors such as lack of alignment with definitive central lab methods, and reluctance to change existing treatment practices are hindering the growth of this market. Moreover, disadvantages of POC testing over central lab methods and recalls of leading glucose monitoring devices are the foremost challenges faced by industry players. New product launches is the key strategy followed by leading market players to ensure their growth in the POC diagnostics market. Moreover, partnerships, agreements, collaboration, and joint ventures; mergers and acquisitions; and expansions are some other growth strategies adopted by industry players in the global market. Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - Industry Trends - Point-Of-Care Diagnostics Market, By Product - Point-Of-Care Diagnostics Market, By Prescription Mode - Point-Of-Care Diagnostics Market, By End User - Point-Of-Care Diagnostics Market, By Geography - Competitive Landscape - Company Profiles - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Bayer Healthcare Ag - Beckman Coulter, Inc. - Becton, Dickinson And Company - Johnson & Johnson - Nipro Diagnostics, Inc. - Roche Diagnostics Limited - Siemens Healthcare Visit http://www.researchandmarkets.com/research/cd...ointofcare
CLIA Waiver for Abaxis' Lipid Profile Tests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 2:20PM CDT
Abaxis received the CLIA waiver status for capillary draw for cholesterol, high density cholesterol and triglycerides.
Abaxis Receives CLIA Waiver For Capillary Sampling For Cholesterol, HDL And Triglycerides
PR Newswire - Fri Mar 28, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today announced the Food and Drug Administration granted CLIA waived status for capillary draw for CHOL, HDL and TRIG. Combined with existing CLIA waived tests for liver diagnostics using capillary samples, Abaxis now has two complete Lipid Panels which can be used by healthcare professionals to diagnose, treat and monitor hyperlipidemia patients using a sample obtained from either venous blood or a capillary draw.
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
Updated Research Report on Abaxis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 2:20PM CDT
On Mar 11, 2014, we issued an updated research report on Abaxis.
Abaxis to Participate in BTIG's Inaugural Snowbird Medical Technology and Diagnostics Conference
PR Newswire - Wed Mar 12, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Don Wood, Chief Operations Officer, will participate in BTIG's Inaugural Snowbird Medical Technology and Diagnostics Conference on Tuesday, March 18, 2014.
Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Wed Mar 12, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mdgmns/rapid_medical) has announced the addition of the "Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid medical diagnostic kits market is experiencing impressive growth globally because of the continuous increase in demand for preventive management of infectious diseases. Since its introduction, rapid medical diagnostic kits are becoming a vital part of the medical diagnostics industry and the scope of this market has been perpetually increasing in terms of detectable diseases and adoption by end users. This report studies the global market for rapid diagnostic kits through three major perspectives namely, application areas, technologies and geography. The application segment of this market has been further segmented into three sub-divisions namely clinical testing, home-use and veterinary diagnostics. In addition, the technology segment of rapid medical diagnostic kits market has been categorized into lateral flow, flow-through, agglutination assays and solid phase. Each of the above segments are analyzed on the basis of their market size (in terms of USD million) for the period 2011 to 2019. This also includes the forecast of the market segments in terms of CAGR (%) for the period 2013 - 2019, considering 2012 as the base year. Geographically, the rapid medical diagnostic kits market is categorized into four regions namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market revenues (for the period 2011 - 2019) and forecast (for the period 2013 - 2019) for each of these regions have been included in this report. The market overview section of the report demonstrates the qualitative analysis of the market dynamics of the global rapid medical diagnostic kits market and thus includes information about the drivers, restraints, opportunities, Porter's five forces model and market attractiveness analysis of this industry. Key Topics Covered: Introduction Executive Summary Rapid Medical Diagnostic Kits Market Overview Global Rapid Medical Diagnostic Kits Market, by Applications, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Technology, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Geography, 2011 - 2019, (USD Million) Recommendations Competitive Landscape Companies Mentioned - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - MegaCor Diagnostik GmbH - F. Hoffmann-La Roche Ltd. - Trinity Biotech plc - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/md...id_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Abaxis, Inc. to Present at the Sidoti & Company Eighteenth Annual Institutional Investor Forum
PR Newswire - Tue Mar 11, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer , will present at the Sidoti & Company Eighteenth Annual Institutional Investor Forum on Tuesday, March 18, 2014 at 10:00 a.m. ET. The conference will be held at the Grand Hyatt New York in New York City.
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
Zacks Rank #5 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (strong sell) List for Monday
Abaxis, Inc. to Present at the Raymond James 35th Annual Institutional Investors Conference
PR Newswire - Thu Feb 27, 7:00AM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer , will present at the Raymond James 35th Annual Institutional Investors Conference on Monday, March 3, 2014 at 10:25 a.m. ET. The conference will be held at the JW Marriott Grande Lakes Hotel in Orlando, Florida.
This Company's "Dismal" Performance Masks Excellent Opportunity
John Leonard, The Motley Fool - Motley Fool - Fri Feb 14, 1:30PM CST
Abaxis fell sharply after reporting disappointing results last month. However the recent recovery suggests the market is beginning to realize that the cause for the "dismal" results (the CEO's words) is most likely a one-off occurrence rather...
Should You Get Rid of Abaxis (ABAX) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 7:30AM CST
It is time to get rid of Abaxis, as it has witnessed a significant price decline in the past four weeks and has seen negative earnings estimate revisions
Abaxis Awarded Veterinary Services Central Fund (VSCF) Contract for Veterinary Diagnostic Laboratory Services from the Department of the Army
PR Newswire - Thu Feb 06, 7:00AM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care instruments and consumables for the medical, research, and veterinary markets worldwide and providing reference lab services to the veterinary and research markets in the United States, announced today that the Department of the Army, Army NAF Contracting has awarded the Company, a contract to provide veterinary diagnostic laboratory services to the Veterinary Services Central Fund (VSCF). This contract provides point-of-care laboratory diagnostic instruments and reagents, as well as reference laboratory services through Abaxis Veterinary Reference Laboratories (AVRL) to approximately 118 Army veterinary activities within the Continental United States (CONUS) and Outside the Continental United States (OCONUS). The period of performance under this contract is for one year, effective immediately with options for four additional one-year periods with maximum order/quantity limitations of $3 million per year.